I may be the earlybird to spread the word but that’s just how strongly I believe you should attend the 2026 Clusterbusters conference in Illinois. Now is the time to lock it in your diaries and lay down some plans! The conferences are truly a life changing experience, I promise you will not regret attending.

The conference is a place where you are certain to make lifelong connections with warriors, learn about emerging research and treatment options, hear directly from doctors and researchers who specialise in cluster headache and importantly, to connect with people who truly get it. There is nothing quite like being in the company of fellow sufferers, of that I can attest. It’s like seeing long lost friends.

Conference Details (2026)

Organisation
Clusterbusters

Dates
Thursday, 8 October 2026 to Sunday, 11 October 2026

Location
Embassy Suites by Hilton in Chicago O’Hare – Rosemont

Official Conference Information
Full details, registration, and updates will be published on the official Clusterbusters conference page once announced.

Hotel and Accommodation
The official conference hotel and discounted room block will be released alongside registration. Booking early is strongly recommended once details go live, as rooms typically fill quickly.

Why This Conference Matters

Clusterbusters does outstanding work across advocacy, peer support, education, research funding and awareness. They bring patients, clinicians, and researchers together in a way that meaningfully advances understanding and care. I have deep respect for their work, they are truly amazing people.

A Personal Perspective

I had the pleasure of speaking at last year’s conference and travelled a long way to attend. One of the standout highlights was the people and culture. Warriors from all over the the United States and beyond, so many accents, all so friendly. I made so many new friends and the icing on the cake was finally meeting people in person that I had been friends with online for nearly ten years, people that I have come to count as close friends (you know who you are).

I learned a great deal and gained even more respect for the doctors and researchers working in this space. Thank you for the work you do. It was genuinely a privilege to meet all of you and I can’t wait to be back in 2026.

If you’d like to check out the Vitamin D3 Regimen presentation I gave then you may do so here.

Lock it in your diary. Commit to it. Start planning for the Clusterbusters 2026 conference today!

For someone hearing about the Vitamin D3 Anti-Inflammatory Regimen for cluster headache for the first time, the loading phase can sound overwhelming. A cumulative 600,000 IU over 6 or 12 days for episodic CH looks enormous on paper, especially when most people are only familiar with daily doses of a few hundred to a few thousand IU.

However, bolus dosing is not unusual in clinical practice. Starship Children’s Hospital in Auckland provides vitamin D3 supplementation recommendations that illustrate this point clearly. When deficiency is suspected or when a child is considered at risk, routine 25(OH)D testing is often unnecessary, and supplementation can be started immediately if there are no contraindications. In cases where daily adherence is unlikely, their guideline even allows for a single annual 600,000 IU dose for children aged five years and older. This high-dose, one-time strategy is known as stoss therapy.

The interesting comparison is not that Starship is a definitive authority for CH, but rather that the dose itself is not unusual. The Vitamin D3 Anti-Inflammatory Regimen uses the same total loading amount as the stoss protocol (600,000 IU), but applies it very differently. Instead of one large bolus, the regimen divides the 600,000 IU across 6 or 12 days. This staged approach quickly elevates serum 25(OH)D while maintaining excellent tolerability in the CH community.

The other key distinction is what follows the loading phase. The cluster headache protocol immediately transitions into a maintenance dose of 10,000 IU daily (adjusted as needed) to keep serum 25(OH)D in the approximate range of 80 to 100 ng/mL. This appears to be the “sweet spot” where the greatest prophylactic benefit is observed. Some patients may require slightly higher levels to achieve a therapeutic response, and from a physiological standpoint this remains achievable with relative safety.

A conservative rule of thumb from bolus-dosing literature is that every 100,000 IU of Vitamin D3 raises serum 25(OH)D by about 10 ng/mL. Given that clinically significant hypercalcemia in most individuals does not manifest until serum levels exceed roughly 200 ng/mL, there is a wide margin between the therapeutic range for CH and the threshold at which toxicity becomes a concern. This is one of the reasons the patient-led regimen has been used successfully and safely by thousands of sufferers worldwide.

You can read the Starship guideline here:
https://www.starship.org.nz/guidelines/vitamin-d-deficiency-investigation-and-management/

The message isn’t to be nonchalant nor to suggest anyone should be casual or careless in their approach to supplementation. If you choose to begin the regimen, do so by following the steps laid out in the Quick Start and Full Reference Guides. Both are available on the main page of www.vitamindregimen.com or in the downloads section. Implementing the protocol correctly gives you the best chance of achieving therapeutic serum levels, maintaining safety, and, importantly, reclaiming your life from this brutal condition.

If you live with cluster headache and haven’t explored the Vitamin D3 Anti-Inflammatory Regimen, you’ll find detailed protocols, safety notes, and real-world experiences at:
www.vitamindregimen.com

Study Overview

This retrospective study evaluated 95 adults with chronic forms of psoriasis treated for up to twelve months using individualised daily doses of vitamin D3 ranging from 30,000 to 60,000 IU per day. All participants discontinued immunosuppressants, corticosteroids, biologics, and phototherapy during the study period, allowing for an isolated assessment of vitamin D3’s effects.

At baseline, 65 percent of patients were vitamin D deficient, with serum 25-hydroxyvitamin D 25(OH)D levels below 30 ng/mL. Within this group, almost 40 percent had levels under 20 ng/mL, representing severe deficiency.

Dosing was stratified by body weight: 30,000 IU per day for individuals between 60 and 75 kg and 40,000 IU per day for those above 75 kg. For patients with 25(OH)D below 20 ng/mL, a loading dose of 600,000 IU administered over ten days (60,000 IU per day) was used before transitioning to daily dosing in close similarity to the 600,000 IU loading dose used for episodic CH upon commencement of the anti-inflammatory regimen. Those with levels between 20 and 29 ng/mL received a 300,000 IU load across five days. Importantly, dosing was adjusted according to parathyroid hormone (PTH) suppression and ionised calcium values rather than 25(OH)D levels alone, a protocol designed to correct vitamin D resistance frequently observed in autoimmune conditions and a foundational premise of the Coimbra protocol.

Clinical Findings

After twelve months, mean PASI (Psoriasis Area and Severity Index) scores improved from 17.83 to 6.52, with 77 percent of participants achieving at least a 50 percent reduction and over 50 percent surpassing 75 percent improvement. Serum 25(OH)D concentrations rose above 100 ng/mL across the cohort, while PTH levels fell from a mean of 52.5 pg/mL to 32.5 pg/mL.

Ionised calcium remained within normal limits throughout, and no cases of hypercalcemia, renal dysfunction or vitamin D toxicity were observed, even in patients receiving up to 60,000 IU per day for several months. This outcome strongly reinforces that when therapy is guided by calcium and PTH monitoring, vitamin D3 can be administered safely at doses far above conventional recommendations.

Why This Matters to Cluster Headache Patients

For cluster headache sufferers using or exploring the Vitamin D3 Anti-Inflammatory Regimen, this study carries particular relevance. The loading protocol in Mahtani’s cohort, 600,000 IU over ten days for patients below 20 ng/mL, is nearly identical to the 600,000 IU loading schedule used in the cluster headache protocol for episodic CH.

However, the key difference lies in maintenance dosing. While the standard CH regimen typically prescribes 10,000 IU per day (or 50,000 IU per week), Mahtani’s patients required 25,000 to 45,000 IU per day on average, with some maintained at 50,000 IU per day for several months before tapering.

For CH patients, this context is highly reassuring. Doses between 10,000 and 20,000 IU per day, often perceived as “high,” are, in reality, modest compared to doses safely employed in other inflammatory diseases such as the Coimbra and LGS protocol. In the psoriasis cohort, even substantially higher doses produced no renal impairment when guided by PTH and calcium monitoring.

Reassessing “High” Doses

In the CH community, many patients are initially anxious about taking 10,000 IU per day, fearing it exceeds safe limits. Yet the Mahtani data make clear that 10,000 IU per day is at the lower end of an established therapeutic range for chronic inflammatory conditions. Even doses four to five times higher have been administered safely under appropriate laboratory oversight. For those with refractory CH who require escalation beyond 10,000 IU per day to achieve PTH suppression and sustained remission, this study provides strong, independent clinical evidence that such dosing can be physiologically tolerated long term.

Conclusion

Mahtani’s 2025 study represents a significant contribution to the broader understanding of vitamin D3’s therapeutic potential. It demonstrates that high-dose daily supplementation, when tailored by individual responsiveness rather than arbitrary limits, can be both effective and safe in chronic immune-mediated disease. For CH patients following the Vitamin D3 Anti-Inflammatory Regimen, it offers an additional layer of reassurance. Both the loading and maintenance strategies align closely with those used in psoriasis but at generally lower doses.

Rather than viewing 10,000 IU per day as excessive, regimen users can take confidence that this amount sits well within a physiologically validated range, and that even higher titrations, if needed for complete CH remission, are safe when done under medical supervision with the appropriate monitoring of labs.

Mahtani R., Singh S., Nair P. M., Singh S. P., Goyal M. (2025). Prolonged high dose daily oral vitamin D3 in the management of psoriasis: A retrospective chart analysis. IP Indian Journal of Clinical and Experimental Dermatology, 11(3), 288-296. https://doi.org/10.18231/j.ijced.89447.1758864688

I’d like to offer a contemporary perspective on recent patient reports from the cluster headache (CH) community alongside my own experience regarding the treatment of CH with nutritional interventions. This draws on a range of emerging research to explore how modulation of the gut microbiota more so than any one diet may present as a novel future therapeutic target in CH. As best I can as a CH patient, I will attempt to integrate the converging lines of evidence that support this hypothesis including a case report, drawn from the grey literature, illustrating the clinical application of such a targeted microbiome-based approach and conclude with some final thoughts on what really is a fascinating subject.

More bacteria than we are human…

The human genome encodes for between 20,000 and 25,000 genes. In remarkable comparison our collective microbial genome, comprised of trillions of microbes that inhabit our bodies, contains an estimated 3,000,000 to 4,000,000 million genes. The gut microbiota is a vast community of bacteria, fungi, viruses and archaea that inhabit the gastrointestinal tract, with the highest density of microbes anywhere in the body found in the colon. The diversity of this community is influenced by a number of factors including diet, environment, motility, autonomic tone, antibiotic exposure, previous infection, vitamin D3 and psychedelics (more on the vitamin D3 and psychedelics later). Their primary energy source is dietary fibre and other non-digestible carbohydrates of which they ferment into short-chain fatty acids (SCFA’s) such as acetate, propionate and butyrate. They also synthesize vitamins such as vitamin K and several B-group vitamins, amino acid derivatives like indole and GABA and secondary bile acids that in turn regulate metabolism and immune function. Together these microbes and their metabolites play an existential role in maintaining gut integrity, modulating inflammation and supporting our overall health.

Balance is the key to life… that sentiment resonates with me…

When this community of microbes is balanced, or in eubiosis, the relationship is mutually beneficial. We nourish the microbes and they nourish us. When the balance of this community is disrupted, disease may follow through a process referred to as dysbiosis. Imbalance of the microbiota may degrade the mucin layer, a protective layer of mucous that protects the epithelial lining of the gut. When the mucosal layer is degraded, disruption may occur at the level of the epithelium where the tight junctions that maintain integrity of permeable membranes are compromised, increasing the translocation of toxins from the gut into blood and lymph where they invoke an immune response. An example of this is lipopolysaccharide (LPS), a structural component of the outer membrane of gram-negative bacteria. LPS engages the toll like receptor 4 (TLR4) complex on innate immune cells, activating the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which translocates to the nucleus and upregulates the expression of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α). This cascade contributes to a process commonly referred to as “leaky gut” syndrome.

Emerging Migraine Research…

Whilst CH and migraine are clinically distinct disorders they do share several overlapping mechanisms including activation of the trigeminovascular system and neurogenic inflammation, as well as responsiveness to medications such as triptans and anti-CGRP monoclonal antibodies such as Emgality. Both conditions also exhibit cyclical patterns and hypersensitivity within pain processing networks. Given the larger body of research on migraine, it is useful to cautiously draw insights from migraine studies given they may reveal potential pathophysiological processes and therapeutic targets relevant to CH.

In my view recent literature seems to have shifted the understanding of migraine from a neurovascular disorder toward a systemic inflammatory condition modulated by the gut-brain-immune axis. Multiple independent studies now converge on the idea that gut dysbiosis and intestinal permeability are central to migraine pathophysiology.

A study by He et al. (2023) confirmed a causal relationship between gut microbial composition and migraine risk, identifying protective taxa such as Bifidobacteriales and pathogenic associations with Anaerotruncus and Clostridium genera, providing what I believe was the first robust evidence that microbiota composition can directly influence migraine susceptibility. In a 2024 study, Vuralli et al. found elevated serum LPS, VE-cadherin, HMGB1 and IL-6 in chronic migraine patients with medication overuse, supporting a “leaky-gut” inflammatory phenotype linked to trigeminal sensitization.

Recent reviews and meta-analyses converge on much the same theme; migraineurs show lower microbial diversity, depletion of SCFA producing species such as Faecalibacterium and Roseburia and a relative overgrowth of pro-inflammatory species. Emerging clinical research supports therapeutic modulation of the microbiota. Grodzka and Domitrz (2025) conducted a meta-analysis that showed probiotic supplementation reduced migraine frequency with mixed effects on severity whilst Kappéter et al. (2023) proposed fecal microbiota transplantation (FMT) as a means of microbial restoration and normalizing the inflammatory mediators implicated in migraine chronification.

What does the CH literature say?

Comparable findings in CH are absent however new evidence does show an emerging persistent inflammatory signature. In peripheral blood, Lund et al. (2025) found distinct cytokine profiles across all CH types with oncostatin M (OSM), an IL-6 family cytokine, elevated in cCH, eCH in-cycle and eCH in remission groups. In cerebrospinal fluid, Ran et al. (2024) demonstrated higher chemokine concentrations with a serum-to-CSF gradient, concentrating inflammation within the central nervous system (CNS) and present both during active cycle and remission periods. More recently, PACAP-38 has also been found to be elevated in CH compared with controls, further supporting the presence of sustained neuroimmune activation involving vasoactive peptides even during remission periods.

And whilst an underlying inflammatory signature has now been identified, the upstream driver of these elevated markers remains unlinked to dysbiosis. Taken together however these new findings point to CH as a condition underpinned by ongoing inflammation within the CNS rather than a series of isolated pain events attributed to dysfunction of the hypothalamus.

So, what was this about a diet? Sign me up!

What has recently been referenced by myself and others in the CH community is a 2018 case-control study by Di Lorenzo et al. that examined the effects of a ketogenic diet in a small cohort of 18 chronic CH patients refractory to standard preventive treatments. The authors reported that 15 participants responded favorably, with 11 achieving sustained pain-free remission and 12 choosing to remain on the intervention even after the study concluded. Although the mechanism of action was not explored, it is my view that the therapeutic benefit of the ketogenic diet likely extends beyond the metabolic effects of ketone production to include modulation of the gut microbiota and its associated inflammatory milieu. To my knowledge, this remains the only dietary intervention in CH and while the sample size was small the findings were nonetheless remarkable.

Here warrior – I recommend giving this a try…

Consider this a brief pause, a half-time reflection, before moving into the following sections. Few examples illustrate the power of patient-led initiatives better than what the CH community has been able to achieve. Out of necessity and sheer persistence, patients have effectively conducted some of the most successful citizen science projects in existence. From the early work exploring psychedelic therapy to the development of the vitamin D3 anti-inflammatory regimen, each step has been driven by individuals determined to find solutions where few existed. These remarkable efforts have produced measurable results and practical treatment tools that continue to change the lives of CH patients, indeed not all heroes wear capes.

Where vitamin D3 & psilocybin converge…

What I find particularly intriguing is that both of these therapies, psychedelic compounds and the Vitamin D regimen, according to emerging research, may exert part of their therapeutic effect through interactions with the gut microbiota. At the same time, their variable efficacy from one CH patient to another may be influenced by the baseline state and diversity of that patient’s microbiome. This bidirectional relationship, in which treatment both shapes and is shaped by its interaction with the microbiota, may help explain why some experience complete remission while others achieve only partial or temporary relief, or require higher or repeated doses. In the following sections, I will examine the literature that highlights the potential points of convergence between Vitamin D and psilocybin, focusing on microbiome mediated interactions.

Oh vitamin D3, you have been kind to me…

For almost a decade now, the Vitamin D3 anti-inflammatory regimen has kept me mostly pain-free from CH. Beyond its role in calcium homeostasis Vitamin D3 plays a key role in maintaining gastrointestinal homeostasis. The active form, 1,25-dihydroxyvitamin D3, binds to the Vitamin D receptor (VDR), which is expressed throughout the intestinal epithelium and immune cells. Through this signaling pathway Vitamin D3 influences epithelial integrity, microbial diversity and modulates the immune response (Vemulapalli et al., 2025).

In refining the original regimen, Pete Batcheller included a B-complex, taking inspiration from Gominak’s work linking Vitamin D restoration to improved sleep and gut function through the microbiota’s production of B vitamins (Gominak, 2016). Gominak proposes that both Vitamin D and the microbiota exist in a symbiotic relationship, where Vitamin D supports the host environment necessary for microbial balance while a healthy microbiota contributes to the production of essential cofactors necessary for neuronal and immune health.

Charoennngam et al. (2020) demonstrated that Vitamin D3 supplementation shifts the microbiota toward a less inflammatory profile, increasing beneficial commensal species such as Bacteroides while reducing pathogenic species like Porphyromonas. In regards to maintenance of the epithelial membranes, Vitamin D3 upregulates tight-junction proteins such as claudins and occludins while lowering zonulin expression, a key marker for intestinal permeability. By strengthening tight junctions Vitamin D3 may limit translocation of bacterial endotoxins such as LPS into systemic circulation (Fedele et al., 2018; Stio et al., 2016).

In addition to maintaining gut barrier integrity, Vitamin D3 modulates the immune response by inhibiting NF-κB activation and reducing the production of pro-inflammatory cytokines while supporting T regulatory cell function and the production of antimicrobial peptides such as cathelicidins and beta defensins (Vemulapalli et al., 2025).

Taken together these findings place Vitamin D3 as a key mediator in gut-immune homeostasis, acting at the bleeding edge between the microbial landscape and host defense. Importantly, as demonstrated by Holick and colleagues in Scientific Reports (2019), the genomic actions of Vitamin D3 are dose and blood-level responsive with higher 25-hydroxy vitamin D levels resulting in broader transcriptional changes across hundreds of genes involved in immune regulation. The fact that Pete Batcheller’s regimen has been assembled into a simple and accessible protocol with consistently impressive response rates is in itself a remarkable achievement given the devastating nature of CH. Whilst Vitamin D3 almost certainly acts on receptors within the trigeminal ganglion and hypothalamus, these recent findings suggest its actions in the periphery, particularly within the gut, may play an important role in the therapeutic efficacy of the anti-inflammatory regimen.

What can mushrooms possibly have to do with any of this?

Intriguing new research suggests that the therapeutic effects of psychedelics, particularly psilocybin, may in part be mediated through interactions with the gut microbiota. While its best described actions involve modulation via the serotonergic receptor, new findings reveal that psilocybin also exerts systemic effects on inflammation, immune signaling, intestinal barrier integrity as well as shaping the microbial landscape itself.

Wang et al. (2025) provide an elegant synthesis of this evolving concept in a recent ACS Chemical Neuroscience viewpoint, suggesting that the therapeutic effects of psychedelics including psilocybin extend beyond cortical serotonergic circuits to modulate the gut-brain axis via interactions with the microbiome. Building on emerging evidence they position these compounds as both neuroactive and immunomodulatory agents, potentially influencing inflammation along the microbiota-gut-brain pathway via NF-κB mediated cytokine modulation as shown in complementary models like Zanikov et al., 2024.

Zanikov et al. (2024) were able to show in a mouse model of colitis that psilocybin reduced gut driven neuroinflammation and lowered the expression of inflammatory cytokines IL-1β, IL-6 and COX-2 in brain parenchyma. These findings link intestinal inflammation directly to a central inflammatory response and confirm that psilocybin’s anti-inflammatory effects occur along the gut-brain axis rather than within the brain alone. Complementary in vitro work in human macrophages shows dose dependent suppression of LPS induced cytokines via modulation of NF-κB signaling, highlighting its broad immunoregulatory potential.

Kelly et al. (2023) introduced the term “psilocybiome” as a framework to describe the bidirectional relationship between psychedelics and the microbiota-gut-brain axis, they propose that microbial diversity and metabolism influence every phase of psychedelic therapy from preparation and acute experience to integration. Caspani et al. (2024) build on this by exploring psychedelics potential antimicrobial effects and how they may reshape gut ecology, suggesting that microbial composition modulates psychedelic pharmacokinetics while remarkably, psychedelics, in turn, remodel the microbiota.

This research suggests that psilocybin’s therapeutic benefit may indeed depend on the baseline composition and inflammatory state of the gut microbiome. This perspective offers a fresh view for the variability in dose response observed within the CH community’s collective busting experiences. It appears reasonable to suspect that interventions which restore microbial balance and support gut integrity may enhance the therapeutic window for psychedelic therapy. Although the degree to which these microbial mediated mechanisms contribute to the therapeutic benefit we see in busting for CH remains speculative, these new findings make clear that psilocybin’s actions reach beyond the mind, extending into the intricate microbial terrain in a complex dance that is beginning to be revealed.

So what about that case report?

Recent clinical evidence provides an example of how restoring microbial homeostasis may be achieved through an integrative approach. A 2023 case report by Beltran and Guimarães described the successful treatment of a patient with psoriasis vulgaris refractory to conventional therapies using a combined anti-inflammatory diet, high-dose vitamin D3 therapy and targeted herbal antimicrobials.

The case report used a diagnostic workup that included the Gastrointestinal Microbial Assay Plus (GI-MAP), a DNA-based stool test that identifies bacterial, fungal and parasitic taxa as well as markers of gut inflammation and intestinal permeability by Quantitative PCR (qPCR). This diagnostic framework provided a precision-based view of the patient’s baseline microbial state and guided subsequent therapeutic choices. Such testing reveals that, just as no two microbiomes are identical, one size may not fit all in nutritional or supplement interventions. Importantly, dysbiosis patterns and their immunological signatures vary between individuals which necessitates personalized modulation of the microbiota rather than blanket probiotic or dietary advice.

In the specific case testing revealed small intestinal fungal overgrowth (SIFO) driven by Candida albicans. These results informed a selection of herbal antimicrobials, notably oregano oil for its antifungal and biofilm-disruptive properties. Oregano oil’s mechanisms include membrane disruption and inhibition of fungal enzyme activity which reduce microbial burden and help restore mucosal homeostasis. To complement this, Curcumin longa (turmeric) was used for its capacity to inhibit NF-κB-mediated inflammation and upregulate VDR expression in epithelial and immune cells.

Following five months of intervention immunofluorescence analysis of VDR expression in skin biopsies revealed upregulation of receptor density compared with baseline, correlating in full clinical remission. This finding parallels the discussion advanced in Beltran’s companion paper, Vitamin D Receptor Renewal Through Anti-Inflammatory Diet, which identifies the suppression of VDR by LPS, mycotoxins and inflammatory cytokines as key drivers of vitamin D resistance in chronic inflammatory and autoimmune diseases. By resolving dysbiosis and improving epithelial integrity through diet, the intervention removed the upstream inflammatory blockade to VDR transcription and restored immune tolerance.

Where and how to even conclude this…?

Cluster headache, long regarded as the most devastating disorder, may find part of its explanation not in the brain alone but in the microbial world that indeed sustains it. As our understanding of the gut-brain-immune axis deepens, the concept that dysbiosis and intestinal permeability may act as upstream drivers of neuroinflammation becomes increasingly difficult to ignore.

While the literature in CH remains in its infancy, speculative bridges are clearly already being built with patents having been filed for microbial modulating technologies aimed at treating headache disorders, such as US9987224B2, which describes methods for altering gut microbiota composition to influence neurological outcomes including migraine and CH. Such developments are another signal of the growing recognition that modulating our microbial landscape presents as an attractive therapeutic target for disorders once considered purely neurogenic in origin.

All being said, it’s early days – what I think we have is an interesting hypothesis more so than settled science for CH specifically. The ketogenic results are impressive but need larger, controlled trials; vitamin D3 works for many but the anti-inflammatory regimen remains without clinical validation in CH and psilocybin’s ties to the microbiome are certainly intriguing but mostly preclinical. All three treatment options are available for patients to pursue at their own discretion.

I hope I have been able to articulate my take on the current literature and of course welcome your thoughts, comments and ideas. Many questions remain covering other important topics in CH such as genetics, periodicity and the role of personality; still – I feel like it is an exciting and hopeful time and look forward to seeing what future research may show in regards CH and the microbiome.

References

Migraine

Vuralli, D., Akgör, M.C., Gök Dağıdır, H. et al. (2024) ‘Lipopolysaccharide, VE-cadherin, HMGB1 and HIF-1α are elevated in chronic migraine with MOH: evidence of leaky gut/inflammation’, J Headache Pain.

Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10875763/

He, Q., Zhang, Y. and Li, R. (2023) ‘A causal effects of gut microbiota in the development of migraine’, J Headache Pain.

Link: https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01609-x

Grodzka, O. and Domitrz, I. (2025) ‘Gut microbiota, probiotics, and migraine: a clinical review and meta-analysis’, Journal of Oral & Facial Pain and Headache.

Link (journal): https://www.jofph.com/articles/10.22514/jofph.2025.043

Kappéter, Á., Zając, A., Domitrz, I. (2023) ‘Migraine as a disease associated with dysbiosis and possible therapy with fecal microbiota transplantation’, Biomedicines.

Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10458656/

Cluster Headache

Lund, N.L.T., Pedersen, S.H., Ashina, M. et al. (2025) ‘Distinct alterations of inflammatory biomarkers in cluster headache: a case–control study’, Annals of Neurology.

Link (journal): https://onlinelibrary.wiley.com/doi/10.1002/ana.27205  

Ran, C., Yang, Y., Guo, S. et al. (2024) ‘Elevated cytokine levels in the central nervous system of patients with cluster headache’, J Headache Pain.

Link: https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-024-01829-9  

Søborg, M.L.K., Amin, F.M., Ashina, M. et al. (2025) ‘PACAP-38 in cluster headache: a prospective, case-control study of a potential treatment target’, Eur J Neurol.

Link (PubMed): https://pubmed.ncbi.nlm.nih.gov/41002104/

Ketogenic Diet

Di Lorenzo, C., Coppola, G., Sirianni, G. et al. (2018) ‘Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: An Open-Label, Single-Arm Clinical Trial’, Frontiers in Neurology.

Link: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2018.00064/full

Vitamin D3

Vemulapalli, R., Thomas, A. (2025) ‘The Role of Vitamin D in Gastrointestinal Homeostasis and Gut Inflammation.’, Int. J. Molecular Sciences

Link: https://pubmed.ncbi.nlm.nih.gov/40243631/

Gominak, S.C. (2016) ‘Vitamin D deficiency changes the intestinal microbiome reducing B-vitamin production in the host: a hypothesis explaining chronic sleep disorder’, Medical Hypotheses.

Link (PubMed): https://pubmed.ncbi.nlm.nih.gov/27515213/

Charoenngam, N., Shirvani, A., Holick, M.F. (2020) ‘The Effect of Various Doses of Oral Vitamin D3 Supplementation on Gut Microbiota in Healthy Adults: A Randomized, Double-blinded, Dose-response Study’, Anticancer Research.

Link: https://pubmed.ncbi.nlm.nih.gov/31892611/

Stio, M. et al. (2016) ‘Vitamin D regulates the tight-junction protein expression in active ulcerative colitis’, Scand J Gastroenterol.

Link (PubMed): https://pubmed.ncbi.nlm.nih.gov/27207502/

Scricciolo A, Roncoroni L, Lombardo V,Ferretti F, Doneda L,Elli L (2018)  ‘Vitamin D3 Versus Gliadin: A Battle to the Last Tight Junction’, Digestive Diseases and Sciences. Link: https://pubmed.ncbi.nlm.nih.gov/29159680/

Shirvani A, Kalajian TA, Song A, Holick MF. (2019) ‘Disassociation of vitamin D’s calcemic and non-calcemic genomic activity & individual responsiveness: RCT’, Scientific Reports.

Link: https://www.nature.com/articles/s41598-019-53864-1

Psychedelics

Wang, X., Li, H. and Zhou, Z. (2025) ‘Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implication’ (Viewpoint), ACS Chemical Neuroscience.

Link (journal page): https://pubs.acs.org/doi/abs/10.1021/acschemneuro.5c00418

Zanikov, T., Gerasymchuk, M. and Robinson, G.I. (2024) ‘Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice’, Biocatalysis and Agricultural Biotechnology.

Link: https://www.sciencedirect.com/science/article/pii/S1878818124000161

Caspani et al. (2024) ‘Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis’, Progress in Neuro-Psychopharmacology & Biological Psychiatry.

Link: https://www.sciencedirect.com/science/article/pii/S1043661824002834  

Kelly, J.R., and Clarke, G. (2023) ‘Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis’, International Journal of Psychopharmacology

Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9791138/

Case Report & Other

Beltran, E.P. and Guimarães, G. (2023) ‘High-dose vitamin D3, anti-inflammatory diet and targeted antimicrobials in psoriasis vulgaris: clinical case with VDR immunofluorescence’, Zenodo case report (grey literature).

Link: https://zenodo.org/record/7799594

Beltran, E.P. (2023) ‘Vitamin D Receptor Renewal Through Anti-inflammatory Diet’, ResearchGate/Institutional page (grey literature).

Link: https://www.researchgate.net/publication/369801068_Vitamin_D_Receptor_Renewal_Through_Anti-inflammatory_Diet_Another_Contributing_Factor_for_Vitamin_D_Resistance

US 9,987,224 B2 (2018) ‘Method and system for preventing migraine headaches, cluster headaches and dizziness.’

Link (Google Patents): https://patents.google.com/patent/US9987224B2/en

People often ask what supplements I use for the Vitamin D3 Anti-Inflammatory Regimen to control my cluster headache. I’m based in New Zealand, and if you’re reading this from overseas, these specific products may not be available in your country. The links below are not affiliate links. They’re simply included to help others who may not have local access or are unsure what to purchase.

This list reflects what I’ve used or currently use. Other CH warriors likely use different brands. Pete, the chronic CH patient who pioneered the regimen, uses different brands too. We live in different countries. This is just to say that you may need to adapt based on what’s available to you, or your preferences for quality, budget, or formulation. This list should provide a decent enough guide to point you in the right direction.

Many people struggle to find a multivitamin that includes the calcium, zinc, boron and retinol. If one of the items is missing, you may do fine without or source that particular item as a standalone supplement.

Important Notes Before You Begin

Always test your vitamin D levels before starting, and monitor regularly. The target 25(OH)D level for this protocol is typically 80 to 100 ng/mL (200 to 250 nmol/L).

Always consult with a physician before starting this or any high-dose supplementation regimen. The loading phase begins with a single 10,000 IU dose of vitamin D3 to ensure no adverse reaction.

For full instructions, safety information, and detailed dosing protocols, download the reference guide available at vitamindregimen.com

Supplement List and Where to Buy

Vitamin D3

10,000 IU Capsules
Source Naturals Vitamin D3 (120 softgels)

Omega-3 Fish Oil

1,040 mg Omega-3 per softgel
Sports Research Omega-3 Fish Oil Triple Strength (90 softgels)

Magnesium

400 mg Magnesium Glycinate (3 tablets per day)
Country Life Chelated Magnesium Glycinate (90 tablets)

400 mg Magnesium Glycinate (2 capsules per day)
Nobi Nutrition Magnesium Glycinate (120 capsules)

Multivitamin

Men’s Formula
Nature Made Multi For Him (90 tablets)

Women’s Formula
Nature Made Multi For Her (90 tablets)

Vitamin K2

MK-4 1,000 mcg and MK-7 100 mcg
Life Extension Super K (90 softgels)

Methylated B-Complex

B-50 Complex
Solaray Methyl B-Complex 50 (60 capsules)

Final Reminders

Many people live in countries where all of these supplements are available over the counter, including high-dose vitamin D3. These links are helpful for those who are unable to obtain the required dosages locally or who face restrictions in accessing specific components.

Because delays in shipping are possible, it’s important to have effective cluster headache abortive therapies available during the waiting period and loading phase. High-flow oxygen remains the gold standard. I personally abort attacks within six minutes using the top-rated Cluster O2 Kit and the correct breathing technique. Prednisone may be considered as a bridging option if needed.

Always consult with your physician before starting the regimen. Ensure that baseline lab tests are completed and that your doctor has reviewed the protocol against any existing health conditions or medications that may contraindicate or preclude vitamin D therapy.

Get Started

To learn more, download the full guide and access further resources at
vitamindregimen.com

If you’re suffering and searching for answers, this protocol might be worth exploring. Start with the guide, take it to your doctor, and take it step by step.

Disclaimer: If monoclonal antibodies (mAbs) have brought you relief, that’s completely valid. This post isn’t about critiquing anyone’s treatment choice – it’s about sharing why I, as a cluster headache sufferer, found the Vitamin D3 regimen a preferable option for me.

Battling the “Beast” with Different Weapons

I’ve tried one, embraced the other and in this post I’ll attempt to compare these options from both scientific and personal perspectives. We’ll look at affordability, accessibility, safety, efficacy, how they work, broader health impacts and the “natural vs synthetic” consideration. My goal isn’t to dissuade anyone who’s benefiting from mAbs but to explain why the Vitamin D3 regimen became my first choice – and in my view presents as a preferable first line prophylaxis to explore for those currently considering what preventative treatment strategy best resonates with their personal preferences.

Affordability: The Cost Factor

One of the biggest differences between mAbs and the D3 regimen is cost. Monoclonal antibodies can come with a hefty price tag. For example, galcanezumab (Emgality), a CGRP mAb often prescribed for episodic cluster headaches, costs around $560-$880 USD per month for a single dose (aafp.org, singlecare.com). That’s hundreds of dollars every month, translating to many thousands per year. Even with insurance, not all plans fully cover these new therapies – patients often face high co-pays or denial of coverage. Some reports estimate that chronic migraine (and cluster) patients on mAbs may pay more than $8,000 a year out-of-pocket for treatment (singlecare.com).

By contrast, the Vitamin D3 regimen is low-cost. High-dose Vitamin D3 capsules, plus the necessary cofactors (like magnesium and vitamin K2), are inexpensive supplements available over the counter. A month’s supply of quality Vitamin D3 (even at 10,000 IU/day or more) and relevant vitamins costs less than $1 US dollar a day. There’s no patent on sunlight or cholecalciferol, so no monopoly pricing. For me, this meant I could afford consistent prevention without begging my insurance or emptying my savings. In a condition that already steals so much from our lives, it was a relief not to have financial stress on top of the physical pain.

Over-the-Counter Convenience

The accessibility gap between mAbs and Vitamin D3 is equally significant. Getting on a monoclonal antibody often requires jumping through hoops: specialist consultations, prescription scripts and sometimes prior authorization from insurance. Because these drugs are injectables typically delivered via specialty pharmacies, they can involve waits and paperwork. Not all doctors are familiar with using CGRP mAbs for cluster headaches (they were initially developed for migraine), so you might struggle to find a willing prescriber or worse still they may not prescribe the correct dose. In some countries, these drugs aren’t even available or approved for cluster headache at all.

The Vitamin D3 regimen, on the other hand, is readily accessible to almost anyone. High-dose Vitamin D3 (10,000 IU capsules, for example) can be purchased at local pharmacies, health stores or online with no prescription in many regions. In others they may be ordered from web stores like iHerb and Amazon. Magnesium, fish oil, vitamin K2, and other cofactors are common supplements. This means no gatekeepers: once you’ve learned the regimen protocol (freely available for download online), you can start immediately and adjust as needed. For me, that autonomy was empowering – I wasn’t waiting on hold for a clinic to call back or for insurer approval. I was able to take control of my therapy on my own terms.

Of course, professional guidance is recommended – discuss the regimen with your doctor and obtain baseline lab tests (vitamin D, PTH and calcium levels) before starting the D3 regimen. But fundamentally, Vitamin D3 put a powerful tool in my hands rather than behind the pharmacy counter so I’d say it is a self-empowering approach, important when cluster headaches often make us feel so damn helpless.

When it comes to safety, both the track record and the nature of these treatments differ greatly. CGRP monoclonal antibodies are a new class of medications. They’re laboratory-produced antibodies designed to block calcitonin gene-related peptide (CGRP), a molecule involved in pain signalling and blood vessel dilation during headaches. Because mAbs are large, complex proteins, they do not cross the blood-brain barrier and largely act on CGRP in the periphery. In clinical trials for migraine and episodic cluster headache, mAbs appeared to be fairly well tolerated in the short term – the most common side effects are injection site reactions and some patients report constipation or fatigue. However, these drugs are synthetic and only a few years old so we lack extensive long-term safety data. There are open questions about how they might affect the body over decades of use (The Journal of Headache and Pain).

For example, any monoclonal antibody can potentially trigger an immune response over time – the body might form anti-drug antibodies that neutralize the mAb or create immune complexes. We simply don’t know yet if subtler issues could emerge after many years (autoimmune reactions? cardiovascular effects from chronic CGRP suppression?), because widespread use only began around 2018. In short, mAbs are effective but new tools, and medicine is still learning about their long-term safety profile.

Vitamin D3, by contrast, is a molecule our bodies know very well. It’s a natural hormone/vitamin that humans produce in the skin from sunlight. The primary risk of Vitamin D is hypercalcemia – too much Vitamin D can raise serum calcium to dangerous levels, leading to kidney stones or calcifications. But this risk is well characterized and easily monitored. Studies have shown that even doses up to 10,000 IU/day are generally safe and well-tolerated, with only mild, transient elevations in calcium in a small percentage of people (PubMed).

Put simply, Vitamin D’s safety parameters are established and predictable – if you supplement responsibly (under medical supervision), the main thing you’ll need are periodic blood tests to ensure your calcium and 25(OH)D levels stay in a healthy range.

Another safety consideration is that mAbs are foreign proteins, whereas Vitamin D3 is bioidentical to what your body makes naturally. Taking Vitamin D is like replenishing something your body is missing; taking a monoclonal antibody is like introducing a foreign (even if friendly) into your system. mAbs being humanized reduces immunogenicity but doesn’t eliminate it – they can provoke immune reactions (The Journal of Headache and Pain). Vitamin D won’t be “attacked” by your immune system since it’s literally part of normal human biochemistry. This gave me additional peace of mind choosing the D3 regimen. I know exactly what I’m putting in my body and how it’s going to be metabolized. The regimen also aligned with a holistic view of health – ensuring you have adequate magnesium, fish oil, etc., which generally benefits your well-being, not just your head. All in all, Vitamin D felt like a gentler, more physiologic approach to prevention, with a safety record that made me comfortable using it indefinitely.

What Works – and for Whom?

Ultimately, efficacy is where “the rubber meets the road.” You can tolerate a lot (cost, hassle, side effects) if a treatment truly works to prevent cluster attacks, they truly are that brutal. So how do mAbs and the Vitamin D3 regimen stack up?

Monoclonal antibodies: The CGRP mAbs have shown mixed, limited results in cluster headache so far. Importantly, none of the CGRP mAbs are approved for chronic cluster headache (the year-round form of CH), because trials did not show clear benefit in chronic sufferers. A large placebo-controlled study of galcanezumab in chronic cluster found no significant difference from placebo in reducing attack frequency (PubMed). This was a major disappointment, underscoring that chronic cluster may involve more complex biology. Galcanezumab (Emgality) did win FDA approval for episodic cluster headache based on a small trial – but even those results, while statistically significant, were modest. In that study of episodic CH patients, about 71% on galcanezumab had their weekly attack frequency cut in half (or better) vs. ~53% on placebo (aafp.org). The drug reduced attacks by roughly 8 per week on average, compared to 5-6 per week reduction with placebo. And notably, its efficacy seemed to kick in within 1-2 weeks but did not eliminate attacks entirely for most. It’s also a short-term intervention: you take 300 mg injections during the cluster bout (up to 8 weeks), and it’s not meant as a continuous year-round preventative. In summary, mAbs might help some cluster patients (particularly episodic cases) get a reduction in attack frequency or intensity – which is wonderful if you’re among those responders. However, many others see little change. This authors impression in the overall sense in the CH community and the literature is that CGRP mAbs are not a miracle cure for cluster headaches; they’re one more tool in the CH toolkit that helps a subset of patients to some degree.

Vitamin D3 regimen: In contrast to the lukewarm clinical data on mAbs, the Vitamin D3 regimen boasts a kind of “underground” efficacy record that is hard to ignore. This patient-led approach – high-dose Vitamin D3 combined with anti-inflammatory cofactors – has been adopted by thousands of cluster headache sufferers worldwide, thanks to advocates in our community (shout-out to chronic CH sufferer “Batch” who pioneered the regimen). While we don’t yet have large randomized trials, we do have extensive anecdotal and survey data suggesting remarkable efficacy. One survey of 110 cluster headache patients on the regimen found about 80% responded with a significant reduction in attack frequency, severity, and duration (clusterheadaches.com). Many report going completely pain-free or into prolonged remission as long as they stick with daily D3. I’m one of those people – after ramping up my Vitamin D3 dose and reaching a high therapeutic blood level of 80-100ng/mL, my attacks stopped and I have been in remission by and large for over a decade.

To be balanced, I’ll note that not everyone achieves 100% relief from Vitamin D3 – there is a subset (perhaps ~20% in surveys) who don’t see improvement, or need additional tweaks (like adding antihistamines or higher doses) to get results. Chronic cluster patients sometimes need higher loading doses to break a cycle. But the overall efficacy signal in the community is strikingly positive. Neurologists have taken notice of these reports: acknowledging that anecdotal patient reports show high-dose Vitamin D can reduce cluster headache burden (Practical Neurology). It’s telling that the cluster community has stuck with this regimen for over a decade – it consistently helps a large portion of us, enough that we’ve effectively conducted a massive “open-label trial” on ourselves. Personally, after years of only partially effective pharma preventives, the Vitamin D3 regimen gave me my life back.

Why might the D3 regimen be so effective for many of us? Part of the answer may lie in how it works compared to mAbs. The two approaches target very different points in the cluster headache pathway – one is reactive (downstream), the other proactive (upstream).

CGRP mAbs – fighting fires after they start: Cluster headaches are associated with a cascade of inflammatory and neurological events. During an attack, trigeminal nerves release a neuropeptide called CGRP (Calcitonin Gene-Related Peptide), which dilates blood vessels and ramps up pain signalling. CGRP is a well-known villain in migraine and cluster headache; infusing CGRP into a person with active cluster can actually trigger an attack (PubMed). The CGRP mAbs work by neutralizing CGRP (or blocking its receptor) in the bloodstream, so that once it’s released, it can’t exert its full effect. In essence, mAbs are like firefighters dousing the flames after the fire has ignited. They don’t prevent the underlying trigger of the headache – they just try to mop up one key messenger (CGRP) downstream. This is a reactive, symptom-directed mechanism. It’s one reason mAbs may reduce attack frequency somewhat, but often don’t stop attacks entirely: by the time CGRP is released and then bound by the antibody, other inflammatory pathways may have already kicked off the pain. Moreover, cluster headaches involve histamine, PACAP, VIP, Substance P and other pathways beyond just CGRP. Blocking one molecule gives a partial solution.

Vitamin D3 – preventing the spark in the first place: Vitamin D works at a more upstream, fundamental level – it’s a potent immunomodulator and anti-inflammatory agent. Rather than targeting one pain molecule, the active form of vitamin D (calcitriol) influences the expression of hundreds of genes, tuning the immune system toward a calmer state. It boosts anti-inflammatory cytokines (like IL-10 and IL-4) and suppresses pro-inflammatory cytokines (like IL-6, TNF-α) (Frontiers in Physiology). It promotes regulatory T-cells that keep the immune response in check. All of this can reduce the overall inflammatory tendency in the body. In cluster headache (and particularly migraine), there’s growing evidence that neuroinflammation plays an important role. By regulating the immune system, Vitamin D3 may prevent those triggers from reaching the boiling point. It’s akin to removing dry leaves and overgrowth before a fire starts, rather than just calling in the fire brigade. There’s even some direct evidence of Vitamin D’s effect on the CGRP pathway: a randomized trial in migraine patients found that vitamin D supplementation significantly reduced serum CGRP levels compared to placebo (The Journal of Headache and Pain).

Vitamin D also supports neuron health and has neuroprotective roles. Cluster headaches are tied to our circadian biology (the hypothalamus is often called the clock that misfires in CH). Vitamin D may help normalize circadian rhythms and hormonal balances indirectly through its widespread actions.

In summary, mAbs act as a targeted blockade once a specific inflammatory mediator (CGRP) is released, whereas Vitamin D3 acts as a regulator, possibly preventing or minimizing the inflammatory signals that lead to an attack in the first place. I find that idea empowering: by optimizing my Vitamin D levels I may be addressing key inflammatory drivers that lead to the conditions where cluster headache present, not just blocking one specific molecule after it’s already been expressed.

The Bonus Health Perks of Vitamin D

One often overlooked advantage of the Vitamin D3 regimen is the broader health benefits it may confer. When I started the regimen, I wasn’t thinking about anything except stopping the hellish pain. But as I stayed on Vitamin D3, I noticed improvements in other areas.

Vitamin D is crucial for bone health and muscle function, as is well known – it helps you absorb calcium and keep your skeleton strong. But it’s also a key player in the immune system. Sufficient vitamin D can enhance your resistance to infections. A large meta-analysis showed that Vitamin D supplementation modestly reduces the risk of acute respiratory infections (like colds and flu) in the general population (PMC).

Furthermore, Vitamin D may offer protection against or improvement in multiple diseases beyond headaches. Research has linked low vitamin D status to higher risk of autoimmune diseases (like multiple sclerosis, rheumatoid arthritis, type 1 diabetes, etc.). A recent randomized trial (the VITAL study) found that older adults taking Vitamin D supplements had a significantly lower incidence of new autoimmune disease diagnoses compared to those on placebo (Harvard Gazette). Vitamin D supplementation over five years cut the risk of developing conditions like rheumatoid arthritis and psoriasis by about 22-30%. That’s huge when you think about population health impact.

While more research is needed, it suggests that keeping your vitamin D level optimized might help prevent some autoimmune processes – a benefit no monoclonal antibody can claim, since mAbs are laser-focused only on CGRP.

Vitamin D’s anti-inflammatory and immune-balancing effects also mean it’s being studied in contexts ranging from heart disease to depression to cancer prevention. The jury is still out on some of these, but one thing is clear: having healthy vitamin D levels is associated with better overall health outcomes and lower inflammation markers. At the very least, by following the D3 regimen, I know I’m not only treating my cluster headaches, I’m also potentially improving my long-term health – strengthening bones, supporting my immune system, and maybe reducing risks of other illnesses. It feels like a holistic wellness step, not a single-purpose drug.

If You Prefer a More Natural Approach…

This point might be more philosophical, but it’s worth noting. The Vitamin D3 regimen is, by design, a natural approach. “Natural” doesn’t automatically mean “better,” but in this case it means we are leveraging the body’s own biochemistry (a hormone the body makes from sunlight) to heal ourselves. Vitamin D3 is cholecalciferol – the exact same molecule your skin produces. It’s as bioidentical as it gets. Taking Vitamin D is like filling up a tank that’s been depleted. Many clusterheads have chronically low vitamin D levels, so it stands to reason that restoring those levels toward an optimal range helps correct something fundamental in our physiology.

Monoclonal antibodies, on the other hand, are synthetic proteins. They are developed in a lab, cultured from cells, and engineered to bind a specific target. Yes, they’re often humanized (made to resemble human antibodies) to reduce allergic reactions, but they are still an artificial medication foreign to our systems. Over time, the body can recognize even humanized mAbs as outsiders – approximately up to 10-18% of patients develop anti-drug antibodies against these therapies (The Journal of Headache and Pain). While often these antibodies don’t cause immediate problems, they can reduce the drug’s effectiveness (neutralizing antibodies) or alter its clearance. In some rare cases with other mAbs, immune complexes formed by antibodies binding to the drug can cause inflammatory reactions.

It may seem a little bit ironic: you take a biologic drug to calm an inflammatory condition, but your body may eventually mount an immune response against that drug, introducing new complexities. This hasn’t been a massive issue with CGRP mAbs so far, but we’ve only used them for a few years – if one day they lose efficacy due to immunogenicity, patients might have to switch meds or go off them.

With Vitamin D3, there’s no such concern. You’re replenishing a nutrient/hormone that your body is evolutionarily designed to utilize. No one will ever develop antibodies to Vitamin D! Instead, your cells will welcome it and put it to work in normal metabolic pathways. I found comfort in the simplicity of that – I wasn’t introducing a complex bioengineered molecule; I was correcting a deficiency and letting my body do what it naturally knows how to do.

To be clear, I’m not “anti-medication” or opposed to synthetic drugs when needed. Modern medicine is amazing, and mAbs are incredible feats of science that help many (especially migraineurs). But for cluster headaches, the natural route of Vitamin D3 just made sense to me. It aligns with our biology and carries an elegance of using the body’s own tools to fight back. Some might call it a home remedy, but it’s backed by solid immunology and an avalanche of real-world success stories.

My Choice and a Call to Hope

Living with cluster headaches is an unimaginable trial. Those who haven’t experienced it may never fully grasp the dread of knowing another attack is coming, or the lengths we’d go to find relief. I’ve written this post not to declare one therapy universally superior, but to shed light on an option that changed my life. The Vitamin D3 regimen gave me back control, health, and hope. It helped to address the root of my problem rather than patching the symptoms. It was affordable, accessible, and empowering – I became an active participant in my healing, not just a recipient of pills and injections. And beyond just stopping headaches, I believe it made me healthier overall.

If you’re someone for whom mAbs work wonders, I celebrate that for you – everyone’s biology is unique. But if you’re someone still suffering, or wary of the cost and unknowns of newer drugs, I encourage you to explore the Vitamin D3 anti-inflammatory regimen. Talk to your doctor about it, get your baseline 25(OH)D level and calcium checked, and see if this natural approach could be your answer. The science supporting it – from the critical role of CGRP and inflammation in cluster headache (PubMed) to the remarkable safety and immune benefits of vitamin D (PubMed, PMC) – is compelling. And the human evidence, the countless stories of cluster warriors finding relief through Vitamin D, is something you simply can’t ignore.

Cluster headaches may be nicknamed the “beast,” but with the right approach, this beast can be tamed. If you’re curious to learn more about the Vitamin D3 regimen that so many of us swear by, I urge you to check out the community and resources at Vitamin D3 for Cluster Headaches. You’ll find detailed guides, dosing protocols and fellow sufferers ready to share their experiences. Empower yourself with knowledge and don’t be afraid to step outside the conventional box – sometimes the best solutions aren’t the newest or most high-tech, but the ones hiding in plain sight.

Readers should note, as sincere as I have attempted to be in this article, I have an underlying bias in favour of the Vitamin D3 regimen given it has kept me in remission from cluster headache for over a decade – I encourage you to be skeptical and always discuss any treatment protocol with your trusted healthcare professional.

Pain-free days may be closer than you think. Stay hopeful, stay informed, and as always, consult your healthcare provider before making changes to your treatment plan. Wishing you clear skies and pain free days ahead.

Understanding the Cluster Headache Cycle

A cluster headache cycle refers to the period when attacks occur frequently, often daily or multiple times per day over several weeks or even months. These cycles are typically followed by remission periods with no headaches. While the exact cause of cluster headaches isn’t fully understood, treatments aim to reduce attack frequency, severity, and duration while preventing future cycles.

Traditional Approaches to Stopping a Cluster Cycle

Prednisone (Corticosteroids)

Prednisone is often used as a first-line treatment to interrupt a cluster headache cycle. It works by suppressing inflammation. A short-term, high-dose taper of prednisone can stop attacks for many sufferers, but prolonged use is avoided due to potential side effects such as weight gain, insomnia, and bone thinning.

Verapamil (Calcium Channel Blocker)

Verapamil is one of the most commonly prescribed preventive medications for cluster headaches. Patients often start with low doses, which are gradually increased. Regular monitoring is required to avoid side effects like low blood pressure and heart rhythm issues.

Monoclonal Antibodies (CGRP Inhibitors)

Newer treatments like monoclonal antibodies (mAbs) target calcitonin gene-related peptide (CGRP), a molecule involved in pain signalling and inflammation. These injections are typically designed to be used monthly as a preventative treatment for cluster.

Oxygen Therapy

High-flow oxygen therapy is a highly effective acute treatment for aborting individual attacks. Breathing pure oxygen via a non-rebreather mask at a minimum flow rate of 10-15 lpm can quickly stop a headache but unfortunately doesn’t prevent future attacks in a cycle.

Breaking or Preventing a Cycle Naturally: The Vitamin D3 Anti-Inflammatory Regimen

For those looking for a preventive more natural approach, the Vitamin D3 Anti-Inflammatory Regimen is a promising option to consider. This regimen aims to reduce systemic inflammation, which may play a role in cluster headache cycles by optimizing Vitamin D3 levels and incorporating key cofactors like magnesium, omega-3 fatty acids, zinc, boron and vitamin K.

Many patients report a significant reduction in cluster headache frequency, severity, or even complete remission from attacks after following the Vitamin D regimen. By addressing potential inflammatory and immune dysfunction at the root, this natural approach works to break or prevent cycles without the side effects of conventional medications.

Which Approach Is Right for You?

Breaking a cluster headache cycle often requires a combination of strategies tailored to the individual. Prednisone, verapamil, and newer mAbs can provide immediate or preventive relief, but they may come with side effects or require careful monitoring.

The Vitamin D3 Anti-Inflammatory Regimen presents as a natural, long-term solution by targeting the underlying inflammation that may trigger cluster cycles. It can be used alongside traditional treatments or as a standalone preventive measure under the care and guidance of your primary care physician.

In Conclusion

Stopping a cluster headache cycle is possible with the right approach. Whether you choose conventional treatments like prednisone and verapamil or explore natural options like the Vitamin D3 regimen, it’s important to find a plan that works for you.

If you’re struggling with cluster headaches, know that there are safe, effective options available to help you manage your condition.

To learn more about the Vitamin D Anti-Inflammatory Regimen, visit The Vitamin D Regimen and download the primary care physicians full reference guide or watch the interview with Pete Batcheller.

With a stroke of luck and a bit of guidance from your primary care physician, the Vitamin D3 Anti-Inflammatory Regimen for Cluster Headache may be the treatment option you’ve been looking for that not only provides relief from cluster headache but also provides additional health benefits without the side effects of traditional medications used to treat cluster headache.

Disclaimer

The information provided here is for educational purposes only and is not intended as medical advice. Always consult with your doctor or healthcare provider before starting any new supplement or treatment regimen, particularly if you have pre-existing medical conditions, are pregnant, breastfeeding, or are taking medications. Your healthcare provider will be able to assess your individual needs, recommend appropriate dosages, and monitor your response to supplements. Never disregard professional medical advice or delay seeking it because of something you have read here.

From a medical standpoint, cluster headaches themselves are not considered life-threatening. They do not cause brain damage, stroke, or other direct physical harm. However, the condition is not without serious risks, especially when viewed through the lens of its broader impact on mental and emotional health.

Mental Health Risks

The nickname “suicide headaches” stems from the significant psychological toll this condition can take. The relentless pain, coupled with its cyclical nature, often leads to feelings of hopelessness, anxiety, and depression. Without proper support, these emotional challenges can escalate, increasing the risk of suicidal thoughts or behaviors, in fact cluster headache sufferers are 20 times more likely to take their own life.

Medication Risks

The severity of cluster headaches drives many sufferers to rely heavily on medications such as triptans or painkillers. Overuse of these treatments can lead to rebound headaches, dependency, or harmful side effects, complicating the management of the condition.

Safety Risks During Attacks

The sudden onset and debilitating nature of cluster headaches can make certain activities, like driving or operating machinery, dangerous. Additionally, nocturnal attacks often disrupt sleep, leading to chronic fatigue, which can further impair daily functioning.

Quality of Life Impacts

The recurring pain, coupled with the fear of the next attack, can lead to social withdrawal, strained relationships, and challenges at work. This erosion of day-to-day life can feel insurmountable for many sufferers.

Why Effective Management Is Crucial

Although cluster headaches are not fatal, the risks associated with their impact on mental health, safety, and overall quality of life make effective management essential. The right approach can help minimize these risks and improve day-to-day functioning.

Conventional Treatments

Acute Treatments: High-flow oxygen therapy and injectable or nasal triptans can quickly abort an attack.

Preventive Medications: Drugs like verapamil, corticosteroids, and lithium are commonly prescribed to reduce attack frequency and intensity during active periods.

Neuromodulation: Devices like vagus nerve stimulators are emerging as options for managing severe cases.

The Role of Chronic Inflammation in Cluster Headaches

Emerging research points to a link between cluster headaches and systemic inflammation. Chronic low-grade inflammation may contribute to the over-activation of the hypothalamus and the trigeminal nerve, both considered key players in the development of cluster headaches. Addressing this inflammation at its source offers a promising pathway for managing the condition.

A Natural, Holistic Approach: The Vitamin D Anti-Inflammatory Regimen

One innovative approach that has gained attention among sufferers and researchers alike is the Vitamin D3 Anti-Inflammatory Regimen. This protocol focuses on reducing inflammation and supporting the body’s immune system through optimal levels of Vitamin D3, combined with key cofactors such as magnesium, omega-3 fatty acids, and vitamin K2.

How It Works

Whilst there is little evidence in published medical journals supporting the use of Vitamin D3 for the treatment of cluster headache, the designer of the regimen and fellow chronic cluster headache sufferer, Pete Batcheller, suggests that Vitamin D3 helps regulate the immune system, reducing the release of pro-inflammatory cytokines that may contribute to cluster headaches.

Many individuals following the regimen have reported significant improvements, including fewer attacks, reduced severity, or complete remission from cluster headache. This natural, non-invasive approach addresses the potential contributing factors that pave the way for the presentation of cluster headaches, offering a long-term solution that complements conventional treatments.

In Conclusion

While cluster headaches are not directly life-threatening, their profound impact on mental health, daily life, and overall well-being can feel dangerous in their own way. Proper management is critical, not just for reducing the frequency and severity of attacks but for reclaiming your quality of life.

If you’re struggling with cluster headaches, know that there are safe, effective options available to help you manage your condition.

To learn more about the Vitamin D Anti-Inflammatory Regimen, visit The Vitamin D Regimen and download the primary care physicians full reference guide or watch the interview with Pete Batcheller.

With a stroke of luck and a bit of guidance from your primary care physician, the Vitamin D3 Anti-Inflammatory Regimen for Cluster Headache may be the treatment option you’ve been looking for that not only provides relief from cluster headache but also provides additional health benefits without the side effects of traditional medications used to treat cluster headache.

Disclaimer

The information provided here is for educational purposes only and is not intended as medical advice. Always consult with your doctor or healthcare provider before starting any new supplement or treatment regimen, particularly if you have pre-existing medical conditions, are pregnant, breastfeeding, or are taking medications. Your healthcare provider will be able to assess your individual needs, recommend appropriate dosages, and monitor your response to supplements. Never disregard professional medical advice or delay seeking it because of something you have read here.

Introduction to the Full Monty

The Antihistamine Full Monty is a powerful supplement protocol designed to address the immune system’s reaction to allergens, which can exacerbate cluster headaches (CH) and migraines. This approach complements the Vitamin D Anti-Inflammatory Regimen by targeting histamine release—a common trigger for headaches. Histamine, produced in response to allergens or infections, can inflame nerves and brain tissues, making CH and migraine episodes more frequent and intense. The Full Monty provides a natural alternative to traditional antihistamines like Benadryl, offering benefits without the drowsiness or long-term side effects associated with those medications.

The Full Monty protocol is particularly useful for individuals who experience little improvement after completing the initial five days of Vitamin D3 loading or those whose headaches return after a period of remission. It can also be started simultaneously with the Vitamin D regimen for migraine sufferers. This protocol works by upregulating the expression of the Vitamin D Receptor (VDR) and supporting immune health with potent antioxidants and anti-inflammatory agents.

Key supplements in the Full Monty include Turmeric (Curcumin), Quercetin, and Vitamin C—all recognized for their ability to combat histamine-induced inflammation. These natural compounds not only reduce histamine levels but also support the body’s immune response by acting as antioxidants, antiviral, and antibacterial agents. For those experiencing chronic headaches, these supplements help manage inflammation and improve the body’s ability to process Vitamin D effectively.

The Full Monty protocol recommends starting with high doses of these supplements (1-2 grams per day of Turmeric, Quercetin, and Vitamin C) and then tapering to lower maintenance doses. For added support, Omega-3 fatty acids, N-Acetyl Cysteine (NAC), Selenium, Zinc, and Melatonin can be introduced depending on individual needs and responses. Together, these supplements work to maintain a stable, headache-free state by mitigating allergic reactions and restoring the balance of inflammatory and anti-inflammatory signals in the body.

Links

People often message me asking what supplements to buy and where to get the items for the full monty. Here is a list below of the supplements along with iHerb links. This is not to offer brand recommendations, buy whatever brand of supplement that you like.

Primary Antihistamine Supplements

A. 1 to 2 Grams/day Turmeric (Curcumin) with Piperine

https://www.iherb.com/pr/nature-s-bounty-turmeric-plus-black-pepper-extract-1-000-mg-60-capsules/86136

B. 1 to 2 Grams/day Quercetin

https://www.iherb.com/pr/kal-quercetin-1-000-mg-60-tablets/106633

C. 1 to 2 Grams/day Resveratrol

https://www.iherb.com/pr/lake-avenue-nutrition-resveratrol-complex-500-mg-250-veggie-capsules/96289

D. 8 Grams/day vitamin C

https://www.iherb.com/pr/california-gold-nutrition-buffered-gold-c-non-acidic-vitamin-c-powder-sodium-ascorbate-8-40-oz-238-g/82704

Optional As Needed

E. 2 Grams/day Omega-3 Fish Oil (EPA and DHA)

F. 250 mcg/day Selenium

https://www.iherb.com/pr/california-gold-nutrition-selenium-yeast-free-200-mcg-180-veggie-capsules/90416

G. 1000 mg/day N-Acetyl Cysteine (NAC)

https://www.iherb.com/pr/lake-avenue-nutrition-n-acetyl-l-cysteine-600-mg-120-veggie-capsules/97436

H. 5 to 10 mg/day Melatonin (Taken at bedtime)

https://www.iherb.com/pr/force-factor-somnapure-great-tasting-melatonin-gummies-dream-berry-10-mg-60-gummies-5-mg-per-gummy/115766

I. 200 to 500 mg/day CoQ10

https://www.iherb.com/pr/california-gold-nutrition-coq10-100-mg-120-veggie-softgels/61074

J. 50 mg Zinc Picolinate*

https://www.iherb.com/pr/california-gold-nutrition-zinc-picolinate-50-mg-120-veggie-capsules/91976

Quick Start Guide

The full monty is detailed in the quick start guide which you can download at here.

Disclaimer

The information provided here is for educational purposes only and is not intended as medical advice. Always consult with your doctor or healthcare provider before starting any new supplement or treatment regimen, particularly if you have pre-existing medical conditions, are pregnant, breastfeeding, or are taking medications. Your healthcare provider will be able to assess your individual needs, recommend appropriate dosages, and monitor your response to supplements. Never disregard professional medical advice or delay seeking it because of something you have read here.